KNE Share Price | Kane Biotech, Inc. Stock Analysis & Recommendation

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Compare Kane Biotech, Inc. with Similar Stocks

RevoluGROUP Canada, Inc.Willow Biosciences, Inc.ASEP Medical Holdings, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Miscellaneous

Market cap

CAD 6 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.36

Return on Equity

194.71%

Price to Book

-5.86

Revenue and Profits:

Net Sales:

0 Million

(Quarterly Results - Jun 2025)

Net Profit:

0 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

33.33%

6 Months

0.0%

1 Year

-61.9%

2 Years

-55.56%

3 Years

-66.67%

4 Years

-66.67%

5 Years

-71.43%

Kane Biotech, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-18.34%

EBIT Growth (5y)

5.15%

EBIT to Interest (avg)

-4.63

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.75

Sales to Capital Employed (avg)

-0.15

Tax Ratio

31.23%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

-5.50

EV to EBIT

-1.70

EV to EBITDA

-1.81

EV to Capital Employed

5.79

EV to Sales

3.13

PEG Ratio

Dividend Yield

ROCE (Latest)

-340.12%

ROE (Latest)

Negative BV

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Bearish

RSI

Bullish

No Signal

Bollinger Bands

Sideways

Mildly Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Bullish

Bearish

Dow Theory

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -100.00% vs 300.00% in Mar 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 75.00% vs -700.00% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.40",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.30",
          "val2": "-1.20",
          "chgp": "75.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.10",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-0.30",
          "val2": "-1.20",
          "chgp": "75.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-11,416.00%",
          "val2": "-3,074.70%",
          "chgp": "-834.13%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 2,000.00% vs -50.00% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 30.43% vs -15.00% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2.10",
          "val2": "0.10",
          "chgp": "2,000.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-4.30",
          "val2": "-3.60",
          "chgp": "-19.44%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.50",
          "val2": "1.20",
          "chgp": "-58.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-3.20",
          "val2": "-4.60",
          "chgp": "30.43%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-2,159.60%",
          "val2": "-25,661.80%",
          "chgp": "2,350.22%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Jun'25

Mar'25

Change(%)

Net Sales

0.00

0.40

-100.00%

Operating Profit (PBDIT) excl Other Income

-0.30

-1.20

75.00%

Interest

0.10

Exceptional Items

0.00

Consolidate Net Profit

-0.30

-1.20

75.00%

Operating Profit Margin (Excl OI)

-11,416.00%

-3,074.70%

-834.13%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jun 2025 is -100.00% vs 300.00% in Mar 2025

Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 75.00% vs -700.00% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

2.10

0.10

2,000.00%

Operating Profit (PBDIT) excl Other Income

-4.30

-3.60

-19.44%

Interest

0.50

1.20

-58.33%

Exceptional Items

0.00

Consolidate Net Profit

-3.20

-4.60

30.43%

Operating Profit Margin (Excl OI)

-2,159.60%

-25,661.80%

2,350.22%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 2,000.00% vs -50.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 30.43% vs -15.00% in Dec 2023

All Annual Results

Company CV

About Kane Biotech, Inc.

Kane Biotech, Inc.

Miscellaneous

Kane Biotech Inc. is a Canada-based biotechnology company. The Company is engaged in the development and commercialization of products that prevent and remove microbial biofilms. The Company's technologies include DispersinB, AloSera, Aledex, Strix NB, bluestem and KBI Disinfectant. It is focused on the companion animal market with Strix NB brand for the veterinary segment and bluestem brand for the pet over the counter (OTC) retail market. The Company markets its oral care technology into the Canadian pet specialty market under the bluestem brand. It has over 100 pet specialty stores in Canada, which are engaged in selling the bluestem oral health products. It has various formulations in development, including formulations with antibiotics and the antibiofilm enzyme beta-N-Acetylglucosaminidase and antibiofilm-antimicrobial formulations for both the veterinary and human markets. It is focused on the development of oral care spray formulation and a water additive powder formulation.

Company Coordinates

Company Details

162-196 Innovation Dr , WINNIPEG MB : R3T 6C5

Tel: 1 204 5000751

http://www.kanebiotech.com

Registrar Details